Safety in a clinical trial is followed well beyond
Post# of 155043
(Total Views: 500)
Posted On: 01/07/2021 1:08:36 PM
Safety in a clinical trial is followed well beyond any primary or secondary endpoint that uses a specific time period. If a patient dies 3 days, 2 weeks, or 5 weeks after a drug is given, that death will be reported as a SAE. Only after unblinding the data will CYDY know when each death occurred along the 28 day time line, if the death occurred after 28 days, and if the death was related to COVID or not. At this point, CYDY only knows that there have been 87 deaths (SAEs) to this point, but does not know which arm those deaths are in, the timeframe of the death, of the cause.
An example of this is the recent pre-print of Dr. A’s 2 patients he treated. Both survived after treatment, but one died due to complications of a feeding tube. Even though the sprints death was not related to leronlimab or COVID, Dr. A had to report the death in the paper. That is the same for the S/C trial.
An example of this is the recent pre-print of Dr. A’s 2 patients he treated. Both survived after treatment, but one died due to complications of a feeding tube. Even though the sprints death was not related to leronlimab or COVID, Dr. A had to report the death in the paper. That is the same for the S/C trial.
(3)
(0)